Spago Nanomedical AB (SPAGO) — Cash Flow-to-Debt Ratio
Spago Nanomedical AB (SPAGO) has a Cash Flow-to-Debt Ratio of -1.04x as of December 2025, meaning its operating cash flow of Skr-6.19 Million could theoretically repay -1% of its total liabilities (Skr5.94 Million) in one year. See Spago Nanomedical AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Spago Nanomedical AB Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Spago Nanomedical AB across 15 annual periods. Also explore Spago Nanomedical AB equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Spago Nanomedical AB (2011–2025)
Year-by-year debt coverage analysis for Spago Nanomedical AB. For market capitalisation and broader financial context, see SPAGO company net worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.77x | Skr-28.30 Million | Skr5.94 Million | ▲ +12.7% |
| 2024 | -5.46x | Skr-34.67 Million | Skr6.35 Million | ▼ -41.9% |
| 2023 | -3.85x | Skr-44.91 Million | Skr11.67 Million | ▲ +11.3% |
| 2022 | -4.34x | Skr-38.19 Million | Skr8.80 Million | ▲ +16.9% |
| 2021 | -5.22x | Skr-35.57 Million | Skr6.81 Million | ▲ +12.5% |
| 2020 | -5.97x | Skr-18.77 Million | Skr3.15 Million | ▲ +18.5% |
| 2019 | -7.32x | Skr-21.29 Million | Skr2.91 Million | ▼ -185.3% |
| 2018 | -2.57x | Skr-10.51 Million | Skr4.10 Million | ▼ -26.5% |
| 2017 | -2.03x | Skr-7.73 Million | Skr3.81 Million | ▼ -112.0% |
| 2016 | -0.96x | Skr-7.86 Million | Skr8.22 Million | ▼ -67.0% |
| 2015 | -0.57x | Skr-5.34 Million | Skr9.33 Million | ▼ -88.0% |
| 2014 | -0.30x | Skr-5.95 Million | Skr19.53 Million | ▲ +22.4% |
| 2013 | -0.39x | Skr-7.74 Million | Skr19.69 Million | ▼ -642.6% |
| 2012 | -0.05x | Skr-601.00K | Skr11.36 Million | ▼ -138.2% |
| 2011 | -0.02x | Skr-276.00K | Skr12.42 Million | — |